These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27482887)

  • 21. BCL6 as a therapeutic target for lymphoma.
    Leeman-Neill RJ; Bhagat G
    Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
    McCoull W; Abrams RD; Anderson E; Blades K; Barton P; Box M; Burgess J; Byth K; Cao Q; Chuaqui C; Carbajo RJ; Cheung T; Code E; Ferguson AD; Fillery S; Fuller NO; Gangl E; Gao N; Grist M; Hargreaves D; Howard MR; Hu J; Kemmitt PD; Nelson JE; O'Connell N; Prince DB; Raubo P; Rawlins PB; Robb GR; Shi J; Waring MJ; Whittaker D; Wylot M; Zhu X
    J Med Chem; 2017 May; 60(10):4386-4402. PubMed ID: 28485934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
    Parekh S; Privé G; Melnick A
    Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
    Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
    J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCL6 confers resistance to HDAC inhibitors in DLBCL.
    Fan G; Zhang Y; Li Q; Rong R; Chen S; He L; Li B; Zhuang W
    Biochem Pharmacol; 2024 Sep; 227():116466. PubMed ID: 39102989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
    Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
    Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
    El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
    Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
    Cerchietti LC; Ghetu AF; Zhu X; Da Silva GF; Zhong S; Matthews M; Bunting KL; Polo JM; Farès C; Arrowsmith CH; Yang SN; Garcia M; Coop A; Mackerell AD; Privé GG; Melnick A
    Cancer Cell; 2010 Apr; 17(4):400-11. PubMed ID: 20385364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.
    Lenz G; Nagel I; Siebert R; Roschke AV; Sanger W; Wright GW; Dave SS; Tan B; Zhao H; Rosenwald A; Muller-Hermelink HK; Gascoyne RD; Campo E; Jaffe ES; Smeland EB; Fisher RI; Kuehl WM; Chan WC; Staudt LM
    J Exp Med; 2007 Mar; 204(3):633-43. PubMed ID: 17353367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
    Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
    J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.
    Cai Y; Abdel-Mohsen M; Tomescu C; Xue F; Wu G; Howell BJ; Ai Y; Sun J; Azzoni L; Le Coz C; Romberg N; Montaner LJ
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
    Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
    Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.